Recent case reports have raised a rare but serious safety question involving semaglutide and a neurological condition called Wernicke encephalopathy. The reports do not prove that semaglutide directly causes this condition. They do suggest that persistent nausea or vomiting, very low food intake, malnutrition, and rapid weight loss can create a setting in which thiamine deficiency becomes dangerous.
This article explains what has been reported, what remains uncertain, and which symptoms should prompt urgent medical attention.
What is Wernicke encephalopathy?
Wernicke encephalopathy is a serious neurological disorder caused by severe deficiency of thiamine, also called vitamin B1. Thiamine is needed for normal brain and nerve function. Without prompt treatment, the condition can cause lasting neurological injury.
It can develop when a person has prolonged vomiting, very poor nutrition, malabsorption, or rapid weight loss. Alcohol use is one possible risk factor, but it is not required. Severe nutritional deficiency can occur for other reasons.
What has been reported with semaglutide?
A 2026 pharmacovigilance study and literature review identified 15 reported cases of Wernicke encephalopathy associated with GLP-1 receptor agonists. Eight involved semaglutide and six involved tirzepatide. These were reports from safety databases, published cases, and clinical records. They are not population studies and cannot establish how often the condition occurs.
A 2026 systematic review focused on Wernicke encephalopathy following semaglutide treatment for obesity and assessed case-based evidence. A recurring pattern was gastrointestinal intolerance, reduced food intake, rapid weight loss, and evidence of nutritional deficiency.
Recent case reports describe serious neurological illness in people using semaglutide who also had prolonged nausea or vomiting, substantial weight loss, and low levels of thiamine or other vitamins. In one report, neurological function improved after vitamin replacement and nutritional treatment. A response in one case does not prove that the medicine caused the illness, but it reinforces the importance of early recognition.
What the evidence does and does not show
The current evidence is a pharmacovigilance safety signal and case-based association. It is not proof that semaglutide or another GLP-1 medicine directly causes Wernicke encephalopathy.
Case reports are useful for identifying unusual problems, but they cannot measure the true frequency of a condition or calculate an individual person risk. The reported illnesses may also involve other factors, including vomiting, reduced food intake, rapid weight loss, diabetes, other medical conditions, and multiple nutritional deficiencies.
The current US FDA prescribing information for Wegovy lists severe gastrointestinal adverse reactions, including nausea and vomiting, and warns about complications related to dehydration. It does not specifically list Wernicke encephalopathy or thiamine deficiency as labeled adverse effects.
Symptoms that should not be ignored
Seek urgent medical assessment for new confusion or changes in mental status, difficulty walking or loss of balance, double vision or unusual eye movements, severe dizziness, or unusual weakness, especially when these symptoms occur with persistent vomiting, very poor food intake, or rapid weight loss.
Ongoing vomiting or inability to keep fluids down also needs prompt medical advice because it can lead to dehydration and nutritional problems. Wernicke encephalopathy is a medical emergency, and early treatment can reduce the risk of permanent neurological damage.
What should people taking semaglutide do?
- Tell your prescriber if nausea or vomiting is persistent, if you are struggling to eat, or if weight loss is unusually rapid.
- Ask your healthcare team whether your nutrition, hydration, and medication plan need review.
- Do not start high-dose thiamine treatment or make medication changes without clinical advice unless an emergency clinician instructs you to do so.
- If you develop confusion, difficulty walking, abnormal eye movements, severe dizziness, or marked weakness, seek urgent medical care rather than waiting for a routine appointment.
The bottom line
Wernicke encephalopathy after semaglutide has been reported, but it appears to be rare and the available evidence does not prove direct causation. The main concern is the combination of severe gastrointestinal symptoms, very low food intake, malnutrition, or rapid weight loss with neurological symptoms.
Semaglutide should not be stopped or adjusted without medical advice in ordinary circumstances. However, emergency neurological symptoms require urgent assessment. Prompt evaluation can help clinicians address dehydration, nutrition, thiamine deficiency, and the medicine plan together.
This article is for general information and is not a diagnosis or a substitute for personal medical advice.
Sources
- Wernicke encephalopathy following semaglutide treatment for obesity: systematic review of case-based evidence
- GLP-1 receptor agonists and Wernicke encephalopathy: pharmacovigilance study and literature review
- Acute nutritional axonal neuropathy in the setting of semaglutide-associated gastrointestinal intolerance
- Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use
- FDA Wegovy prescribing information, revised February 2026